Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities Dec 18, 2023
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP Dec 13, 2023
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells Nov 7, 2023
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia Aug 15, 2023
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030 Jul 25, 2023
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors Jul 5, 2023
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe May 25, 2023
